HeartBeam Inc Dossier - Source-backed chat

HeartBeam Inc

BEATNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)-0.20

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.42Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $23.6M

Enterprise Value $14.9M

Shares Outstanding 48.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

HeartBeam, Inc. is transitioning from a pre-revenue development-stage medical technology company to an active commercial player in the digital cardiology space. Following critical FDA 510(k) clearances for its 3D ECG technology (December 2024) and its synthesized 12-lead ECG software (December 2025), the company is executing a highly targeted, high-margin commercial launch. By focusing initially on the premium concierge and preventive cardiology markets—where patients are highly willing to pay out-of-pocket—HeartBeam bypasses immediate reimbursement hurdles while building clinical validation. Backed by a strong intellectual property portfolio of over 20 patents and a newly fortified balance sheet from an $11.5 million capital raise in April 2026, HeartBeam is well-positioned to disrupt the $2 billion ambulatory ECG monitoring market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$3.38

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

Commercial adoption in the concierge segment is slower than anticipated due to limited physician outreach and high out-of-pocket costs for patients. Clinical trials for heart attack detection face enrollment delays, pushing back the FDA submission timeline. The company's cash burn increases, requiring further dilutive equity financing before achieving self-sustaining commercial scale.

Base CaseCentral scenario

$4.1360%

HeartBeam successfully executes its limited commercial launch with ClearCardio and other early-adopter concierge practices, establishing steady initial revenue. The company completes the ALIGN-ACS study in Q3 2026 and finalizes the FDA pivotal study design by Q4 2026. Cash runway is extended comfortably into 2027 due to the $11.5 million capital raise, allowing the company to meet its near-term clinical and operational milestones.

Bull CaseUpside scenario

$5.0025%

Rapid adoption within the premium concierge cardiology segment drives high-margin recurring subscription revenue. The ALIGN-ACS study yields outstanding clinical data, leading to a swift FDA clearance for home-use heart attack detection. Strategic partnerships for the 12-lead ECG patch are secured ahead of schedule in Q3 2026, unlocking non-dilutive funding and accelerating market entry.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-ever cable-free, credit-card-sized device capable of synthesizing a clinical-grade 12-lead ECG at home.
Strong intellectual property protection with over 20 issued patents covering its 3D ECG technology.
Targeting a high-value, low-friction entry point in the premium concierge medicine market with annual subscription pricing of $500-$1,000 per patient.
Fortified balance sheet following an $11.5 million underwritten public offering in April 2026, reducing near-term liquidity risks.

Key Investment Risks

Pre-revenue status leaves the company highly dependent on successful commercial execution and capital markets.
Intense competition from established players in the ambulatory cardiac monitoring and wearable ECG markets.
Regulatory risks associated with obtaining future FDA clearances for heart attack detection and the continuous-wear patch.
Reliance on direct-pay/out-of-pocket models initially, with long-term growth dependent on securing broad insurance reimbursement.

Thesis Invalidation Triggers

Failure to secure strategic partnerships for the 12-lead ECG patch program by the end of 2026.
Significant delays or negative outcomes in the ALIGN-ACS clinical study.
Quarterly cash burn accelerating beyond $4.5 million without corresponding revenue growth.
Inability to expand commercial partnerships beyond the initial concierge cardiology groups.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.